All In Biotech

Drug Trial Radar · NCT06860243

A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)

An Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of MK-5684 in Male Participants With Moderate Hepatic Impairment

Last checked: Nov 19, 2026Latest source record: Feb 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

May 13, 2025

Primary completion

Feb 9, 2026

Study completion Feb 19, 2026

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Mar 5, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to opevesostat in the body when it is given to healthy participants and participants with moderate hepatic (liver) impairment.

Conditions

  • Hepatic Impairment
  • Healthy Participants

Interventions

  • OpevesostatDrug

    Oral film-coated tablet

  • PrednisoneDrug

    Oral tablet

  • Fludrocortisone acetateDrug

    Oral tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Concentration Versus Time Curve from 0 to Infinity (AUC0-inf) of OpevesestatTime frame: At designated timepoints (up to approximately 96 hours post-dose)
  2. Area Under the Concentration Versus Time Curve from 0 to the Last Quantifiable Sample (AUC0-last) of OpevesestatTime frame: At designated timepoints (up to approximately 96 hours post-dose)
  3. Area Under the Concentration Versus Time Curve from 0 to 24 hours (AUC0-24) of OpevesestatTime frame: At designated timepoints (up to approximately 24 hours post-dose)
  4. Maximum Observed Concentration (Cmax) of OpevesestatTime frame: At designated timepoints (up to approximately 96 hours post-dose)
  5. Time to Maximum Concentration (Tmax) of OpevesestatTime frame: At designated timepoints (up to approximately 96 hours post-dose)
  6. Apparent Terminal Half-life (t1/2) of OpevesestatTime frame: At designated timepoints (up to approximately 96 hours post-dose)
  7. Apparent Clearance (CL/F) of OpevesestatTime frame: At designated timepoints (up to approximately 96 hours post-dose)
  8. Apparent Volume of Distribution During Terminal Phase (Vz/F) of OpevesestatTime frame: At designated timepoints (up to approximately 96 hours post-dose)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Clinical Pharmacology of Miami ( Site 0002)

    Miami, Florida

  • Texas Liver Institute ( Site 0001)

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.